BillionToOne pushes the boundaries of molecular diagnostics through quantitative technologies. Our molecular counter platform is the only technology that can accurately count the DNA molecules at the single base-pair single-count level. This technology increases the resolution of cell-free DNA diagnostics by over 1000-fold and unlocks a wide range of prenatal and oncology applications. Our first product, UNITY, enables non-invasive detection of single gene disorders such as cystic fibrosis, sickle cell disease, spinal muscular atrophy, and thalassemias from a single blood tube taken from the pregnant mother. These are the most common genetic disorders in the world (with more than 100 million carriers), and their prenatal detection currently requires invasive methods with high miscarriage risk. UNITY has achieved 100% accuracy in clinical trials and is going to be available in May.
BillionToOne has raised funding from global, prominent institutional funds such as Hummingbird Ventures, NeoTribe Ventures, and Y Combinator, as well as from prominent angel investors who previously invested in SpaceX, Box, and Palantir.